MP Biomedicals, A*Star co-develop rapid antibody test kit for Covid-19

Vivienne Tay

Vivienne Tay

Published Fri, Jul 24, 2020 · 08:04 AM

DIAGNOSTIC corporation MP Biomedicals Asia Pacific and the Agency for Science, Technology and Research (A*Star) have partnered to create a rapid antibody test kit for the Covid-19 virus.

Called the ASSURE SARS-CoV-2 IgG/IgM rapid test, the test produces accurate results in 15 minutes and employs a lateral flow format similar to those used in home pregnancy tests, MP Biomedicals and A*Star said in a joint statement on Friday.

The test kit was developed and manufactured in Singapore and has been granted provisional authorisation by the Health Sciences Authority for its use in the country.

It can be deployed at or near the point of patient care and has been distributed to regions such as Europe, Africa and South America. MP Biomedicals intends to file for emergency use authorisation for the product from the US Food and Drug Administration.

MP Biomedicals and A*Star said the test kit can be used to determine whether an individual has been previously exposed to the virus and generated antibodies as a result. This can help identify asymptomatic individuals or those with mild symptoms who were not subjected to RT-PCR testing.

To avoid giving patients false reassurance they do not have the Covid-19 infection due to a negative result, MP Biomedicals and A*Star said the kit should not be used in the clinical diagnosis of Covid-19 infections or in the evaluation of persons with acute respiratory symptoms, especially in the first 14 days of illness.

BT Short Logo

THE BUSINESS TIMES INSIGHTS

Powering Asean's Future 2026

Find out how enterprises are navigating power constraints and sustainability targets

ACCESS THE INSIGHTS

In the collaboration, MP Biomedicals use proprietary synthetic Covid-19 proteins to develop the product based on its lateral flow platform.

The Diagnostics Development (DxD) Hub, a national platform hosted by A*Star's commercialisation arm A*ccelerate, co-developed the validation protocol and quality controls.

The ASSURE rapid antibody test kit was evaluated by the National University Hospital's (NUH) Department of Laboratory Medicine, demonstrating "good results" for both serum and whole blood. 

The sensitivity of the kit performed well as compared to commercial immunoassays when tested with convalescent blood from recovered Covid-19 patients in the clinic, the statement said.

DxD Hub chief executive officer (CEO) Sidney Yee said: "It is absolutely critical that we continue to transfer R&D know-how to biotech companies, to scale up and let more labs tap on this diagnostics test kit to screen patients."

Delynn Xu, MP Biomedicals senior research and development (R&D) manager said: "We are not the first one in the market but chasing the best performance is always our primary goal. With this rapid antibody test kit, we are proud to contribute to the global fight against Covid-19."

Temasek Foundation - which falls under the philanthropic arm of Temasek Holdings - placed an undisclosed amount of initial commitment to help MP Biomedicals scale up their production locally and pilot its use in the local community.

Temasek Foundation CEO Ng Boon Heong said the organisation seeks to actively pilot innovative solutions for community care.

"These kits help identify segments of our communities that are recovering from or previously infected by SARS-CoV-2 to ensure their safe return back to work," he said.

Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.

Copyright SPH Media. All rights reserved.